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Mal de Meleda is an autosomal recessive inﬂammatory and keratotic palmoplantar skin disorder due to
mutations in the ARS B gene, encoding for SLURP-1 (secreted mammalian Ly-6/uPAR-related protein 1).
SLURP-1 belongs to the Ly-6/uPAR superfamily of receptor and secreted proteins, which participate in signal
transduction, immune cell activation or cellular adhesion. The high degree of structural similarity between
SLURP-1 and the three ﬁngers motif of snake neurotoxins and Lynx1 suggests that this protein interacts with
the neuronal acetylcholine receptors. We found that SLURP-1 potentiates the human a7 nicotinic
acetylcholine receptors that are present in keratinocytes. These results identify SLURP-1 as a secreted
epidermal neuromodulator which is likely to be essential for both epidermal homeostasis and inhibition of
TNF-alpha release by macrophages during wound healing. This explains both the hyperproliferative as well
as the inﬂammatory clinical phenotype of Mal de Meleda.
INTRODUCTION
Mal de Meleda (MdM, OMIM 284300, syn. keratosis
palmoplantaris transgrediens of Siemens), is an autosomal
recessive palmoplantar keratoderma originally described in
patients from the island of Meleda, Croatia (1). It is character-
ized by an inflammatory, malodorous, sharply demarcated,
palmoplantar keratoderma, involving palms and soles and
extending on (‘transgressing’) the back of hands and feet as
well as the wrists and heels. Frequently associated features are
hyperhidrosis, perioral erythema and lichenoid or keratotic
plaques over joints, brachydactyly with cone-shaped fingers
and nail abnormalities such as koilonychia or pachyonychia
(2). The Mal de Meleda gene is located on chromosome 8q24.3
within a cluster of Ly-6 homologous human genes (3), and
mutations in the ARS B gene, encoding for SLURP-1 (secreted
mammalian Ly-6/uPAR-related protein 1), were found to
underlie the disease in over 25 unrelated incidences (4–6).
The Ly-6/uPAR superfamily of receptor and secreted proteins
contains a carboxy-terminal consensus sequence motif
CCXXXXCN and one or several repeats of the Ly-6/uPAR
domain, which is defined by a distinct disulfide bonding pattern
between eight or 10 cysteine residues (7–9). They can be
classified into two subfamilies on the basis of the presence or
absence of a GPI-anchoring signal sequence (10).
GPI-anchored Ly-6/uPAR receptor proteins include the retinoic
acid-induced gene E (RIG-E, or human Ly-6E), the E48
antigen (human Ly-6D), Ly-6H, the PSCA, CD59 or protectin,
lynx1 and uPAR (11–15). The E48 gene is known to be
expressed in human keratinocytes, but not in lymphocytes, and
modulates desmosomal cell–cell adhesion of keratinocytes
(12,16). The urokinase-type plasminogen activator receptor
(uPAR) interacts in dynamic association with integrins and
initiates signaling events that alter cell adhesion, migration,
proliferation and differentiation (for review see 17). uPAR is a
distant Ly-6/uPAR family member and, contrary to other
members, contains three contiguous copies of the Ly-6/uPAR
domain, differential cleavage of which regulates its multiple
functions (18,19). The second subfamily with a Ly-6/uPAR
domain but no GPI-anchoring signal sequence includes
SLURP-1, a 9 kDa protein encoded by the ARS B gene and
the recently reported SLURP-2 (10,20). Phylogenetic analysis
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based on the SLURP-1 primary protein structure revealed a
close relationship to the subfamily of single-domain snake and
frog cytotoxins, i.e. a-bungarotoxin (Bgtx) and a-cobratoxin
(Cbtx). Thus, SLURP-1 is expected to fold similarly to the
snake neurotoxins (21) and contains a signal peptide (amino
acids 1–22), suggesting that it could be secreted. Although it
has been shown that mutations of SLURP-1 are implicated in
MdM, its molecular function remained unknown. SLURP-1
may function as a ligand for a receptor yet to be identified, e.g.
in intercellular adhesion as has been shown for E48 (Ly-6D)
and its ligand Ly-6D-L (22).
The high degree of structural homology between SLURP-1
and the snake neurotoxins suggests that it may interact with ion
channels, in a way comparable to the action of Lynx1, a GPI-
anchored Ly-6/uPAR protein with structural and functional
similarity to snake venom toxins. Lynx1 has been shown to
interact with neuronal nicotinic acetylcholine receptors in the
central nervous system where it modulates the cellular calcium
permeability (23). a7 nicotinic receptors have been reported to
play a central role in the differentiation of stratified squamous
epithelium (24).
In this study we isolated, purified and characterized the
SLURP-1 protein. We demonstrate that SLURP-1 is secreted
by N-terminal signal cleavage and acts as a neuromodulator
of the a7 nicotinic receptor (a7 nAChR), suggesting that it
may regulate epidermal calcium homeostasis and cutaneous
inflammation.
RESULTS
SLURP-1 is a propeptide cleaved prior to secretion
To assess whether SLURP-1 is indeed secreted and to test for
the actual presence of the putative cleavage site of the signal
sequence, we produced recombinant protein SLURP-1 with an
N-terminal haemaglutinin (HA) tag and a C-terminal myc tag
(Fig. 1A). After transient transfection of 293T cells we
identified SLURP-1 48 h later in the culture medium by
immunoblotting with anti-myc antibodies. The absence of the
HA-tagged protein (Fig. 1B) suggests that SLURP-1 is cleaved
before secretion.
We purified recombinant polyhistidine-tagged SLURP-1 by a
cobalt affinity chromatography with Talon resin (Clontech).
Most proteins did not bind the resin, and remained in the flow-
through fraction (Fig. 2A). We eliminated co-purified proteins
by gel filtration (BioRad BioPrepSE-100/17) to obtain pure
recombinant SLURP-1 (Fig. 2B). The estimated final yield was
about 100 mg of protein per liter of culture medium.
SLURP-1 is a non-glycosylated protein
SLURP-1 contains a putative N-glycosylation site on N64.
Since glycosylation could change biological properties, we
incubated partially purified SLURP-1 produced in mammalian
and insect cells (not shown) with N-glycosidase F, which
hydrolyses N-glycan chains. Contaminating proteins were used
as internal positive control. The shift in the migration in some
of these proteins indicates the proper functioning of the
enzyme. This condition does not modify the migration of
SLURP-1 (Fig. 1C), indicating that SLURP-1 is not glycosy-
lated. However the method used is based on a shift in molecular
weight of the protein, and thus may not detect glycosylation
from a single residue.
SLURP-1 can modulate nicotinic acetylcholine
function in vitro
Phylogenetic analysis based on the SLURP-1 amino acid
sequence reveals a close relationship to the subfamily of single-
domain snake and frog cytotoxins, i.e. a-bungarotoxin (Figs 3A
and 5). Three-dimensional structure analysis of SLURP-1
suggests that this protein may resemble that of other Ly-6 proteins
and three fingered frog and snake venom toxins, i.e. CD59 and
a-bungarotoxin (Fig. 3B). To test whether SLURP-1 might be
functionally homologous to the venom toxins and act on nAChRs,
we examined ACh-elicited macroscopic current responses in
control and SLURP-1-treated Xenopus oocytes expressing
recombinant human a7 nAChRs (Fig. 4). We measured ACh-
evoked responses before and after exposure (2.5–5min) to highly
purified SLURP-1. SLURP-1 enhanced the amplitude of theACh-
evoked macroscopic currents in a concentration-dependent
manner. At a concentration of 200 pM, SLURP-1 increased the
amplitude of the ACh-evoked macroscopic currents by 421
130% (n¼ 6), and 20 nM SLURP-1 enhanced the amplitude by
1214 550% (n¼ 4), comparedwith control (Fig. 4A). SLURP-1
applications exhibited similar activity with all the ACh concen-
trations tested, except 10mM. The dose–response curve indicates
that SLURP-1 potentiates a7 nAChR homopentamers, since the
EC50was 175mMACh for the controls and dropped to 68mMACh
after SLURP-1 treatment (Fig. 4B). The effects of SLURP-1 on
the ACh dose–response curve indicate that 200 pM causes an
increase in both current amplitude and sensitivity to ACh as well
as an increase in the Hill coefficient. Application of SLURP-1 did
not evoke currents in the absence of ACh. Thus, SLURP-1
functions not as a ligand or neurotransmitter, but modulates
receptor function in the presence of its natural ligand in a manner
consistent with an allosteric mode of action.
DISCUSSION
The association between the keratotic palmoplantar skin
disorder called Mal de Meleda and mutations in SLURP-1
suggests that alteration of this secreted protein may disrupt the
homeostasis of the skin. Additionally, SLURP-1 modification
could modify the secretion from macrophages of TNF-a, a
pleiotropic cytokine factor that has been shown to elicit
inflammatory responses.
The high degree of structural similarity between SLURP-1
and the three-fingered protein family, and the expression of a7
nicotinic acetylcholine receptors in keratinocytes, as well as the
role of these receptors in macrophage secretion, point to a
possible role of SLURP-1 at this specific ligand-gated channel.
Secreted snake a-neurotoxins are known to interact with the
muscle and neuronal subtypes of the nicotinic acetylcholine
receptor (nAChR), and both muscarinic and nicotinic AChRs
are expressed in keratinocytes (25,26). Epidermal nAChRs are
involved in regulating cell adhesion and motility of epidermal
keratinocytes (27), and nicotine exerts inhibitory effects on
keratinocyte migration. nAChRs have been demonstrated to
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play a role in wound healing (28). The effects of nicotine may
be mediated by a3 and a7 nAChRs with Ca2þ serving as a
second messenger in this signaling pathway (29). Calcium has
an established role in the homeostasis of mammalian skin, and
a gradient of calcium concentration increasing from the basal
layer to the stratum granulosum modulates keratinocyte
proliferation and differentiation (30,31). Recent data revealed
that homomeric a7 nAChRs actively participate in the control
of epidermal differentiation. Indeed, elimination of the a7
signaling pathway was reported to block nicotine-induced
influx of 45Ca2þ and to inhibit expression of markers of
epidermal differentiation (24). Thus, ACh signaling through a7
nAChR channels appears to be functional in keratinocytes and
essential for epidermal homeostasis. TNF-a is a pleiotropic
proinflammatory cytokine that elicits a large number of
biological effects, including inflammatory and immunoregula-
tory responses (32). TNF-a is known to be released from
keratinocytes after stimulation with lipopolysaccharide (LPS),
ultraviolet (UV) light or wound healing and participates in
cutaneous inflammation (33). In turn, upon stimulation
with proinflammatory cytokines such as TNF-a and IL-1,
keratinocytes synthesize and release LARC/CCL20, which
attract CCR6-expressing immature dendritic cells and memory/
effector T cells into the dermis of inflamed skin (34).
Macrophages play a significant role in skin inflammation,
since they release TNF-a after activation, thereby amplifying
the inflammation regulatory loop. ACh inhibits the release of
TNF-a and other cytokines on primary macrophages, through a
mechanism dependent on bungarotoxin-sensitive receptors
(35). The a7 nAChR subunit is required for inhibition of
TNF-a release by macrophages (36), and inactivation of this
pathway can contribute to excessive systemic release of
cytokines during endotoxaemia or other injury.
In this study, we identify SLURP-1 as a novel modulator of
the human a7 nicotinic acetylcholine receptor. The lack
of action of SLURP-1 alone and its important potentiation of
the agonist response suggests that SLURP-1 acts as a positive
allosteric effector at the a7 receptor. This hypothesis is further
supported by the increased ACh sensitivity and increased
apparent cooperativity that are hallmark of allosteric effectors
(37). While it remains to be demonstrated that point mutations
observed in SLURP-1 disrupt its effect at the a7 receptor, other
Figure 1. SLURP-1 is a non-glycosylated protein whose signal sequence of SLURP-1 is cleaved during processing. (A) SLURP-1 construct tagged with HA-tag in
N-terminus and myc-tag in C-terminus, respectively. (B) Culture medium was collected after 24 h and directly immunoblotted with anti-myc or anti-HA antibodies.
The presence of a myc-tagged protein but not HA-tagged in the culture medium suggests that the signal sequence is cleaved during intracellular processing.
(C) After N-glycosidase treatment, as described in Methods, proteins are loaded on SDS–PAGE and revealed either by silver staining or immunoblotted with
anti-myc antibody. Arrows indicate co-purified deglycosylated protein not present before N-glycosidase treatment.
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variants such frame shifts mutations will certainly result in
truncated, misfolded and therefore non-functional proteins.
Since Mal de Meleda is characterized by a clinical phenotype
with marked cutaneous inflammation and is due to absent or
mutated SLURP-1, this raises the possibility that SLURP-1
controls TNF-a release in dermal macrophages and in
keratinocytes by activation of nAChRs and thus reduced
inflammation. The identification of SLURP-1 as a modulator of
nAChRs will allow to further define the role of secreted Ly-6




For expression in mammalian cells, the cDNA encoding
for SLURP-1 was modified by PCR to add 50HindIII and
30XbaI restriction sites at their termini with the following
primers: sense, 50-AAGCTTGGAGCAATGGCCTCTCGCTGG
and antisense, 50-TCTAGAGAGTTCCGAGTTGCAGAGGTC.
The PCR fragments were purified from agarose gels and ligated
into HindIII- and XbaI-digested pBudCE4 (Invitrogen) to give
the plasmid pBud-SLURP-1, which allowed addition of a C-
terminal myc tag for detection by western analysis and His6 tag
for purification. To generate the recombinant SLURP-1 protein
with tags at both N- and C-termini, the cDNA encoding for
SLURP-1 was amplified from pBud-SLURP-1 by PCR using
primers containing 50EcoRVand 30BglII restriction sites at their
termini and including the myc tag. The following primers were
used: sense, 50-GAGATATCGGAGCAATGGCC-TCTCG and
antisense, 50-AGAGATCTTCACAGATCCTCTT-CTGAGATG
AGTTT. The PCR fragments were purified from agarose gels
and ligated into EcoRV- and BglII-digested pCRUZ-HA (Santa
Cruz), to generate pCSLURP-1, which allowed addition of an
N-terminal haemagglutinin (HA) tag (see Fig. 2).
The resulting plasmids were then used to transform
competent XL1-Blue cells. Single colonies were picked, and
plasmid DNA was isolated and purified using reagents from
Qiagen according to the manufacturer’s instructions. For
expression in insect cells, the pBud-SLURP-1 plasmid was
digested by HindIII and EcoRV. The fragment corresponding to
SLURP-1 cDNA with a myc tag at C-terminus was purified
from agarose gels and ligated into HindIII- and XbaI-digested
pIZ (Invitrogen), thus generating pIZ-SLURP-1, which
encodes for the same protein as pBud-SLURP-1, including
Figure 2. Purification of SLURP-1 from culture medium. (A) 293T-SLURP-1 stable cell line were generated by calcium phosphate transfection and Zeocin
selection. Culture medium was collected after 72 h. His6-tagged SLURP-1 was purified from culture medium with Talon resin. Fractions were loaded on a 15%
SDS–PAGE. Proteins were revealed either by silver staining or immunoblotted with anti-myc antibody. Lane 1, input; lane 2, flow-through; lane 3, wash 1; lane 4,
wash 2; lane 5, elution 1; lane 6, elution 2. (B) Silver stained SDS–PAGE (15% acrylamide) of recombinant SLURP-1 following purification with Talon resin and
size exclusion chromatography.
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myc and His6 tags. Correct insertion and in frame cloning of all
plasmids was verified by sequencing.
Cell lines
HEK 293T cells (ATCC CRL-11268) were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum (Gibco), 2mM L-glutamine, 100 units/ml
penicillin, and 100 mg/ml streptomycin, at 37C in a 5% CO2
humidified atmosphere. The cells were harvested by trypsiniza-
tion when 90% confluent and plated at split ratios of 1 : 5.
Stable cell lines expressing SLURP-1 were generated by
calcium phosphate transfection of pBud-SLURP-1 as previously
described (38) and Zeocin selection. Clonal cell lines were
isolated by the dilution method. Trichoplusia ni (HighFive,
Invitrogen) cells were maintained at 27C in Express Five1
SFM medium (Life Technologies). To generate stable cell lines,
10 mg of pIZ-SLURP-1 was transfected in HighFive cells with
CellfectinTM according to the manufacturer’s instructions.
Zeocin was added 48 h later for selection. Clonal cell lines
were isolated with cloning cylinders.
Purification of recombinant SLURP-1
Recombinant SLURP-1 was purified using the His6 tag from
the culture medium of stably transfected mammalian and insect
Figure 3. SLURP-1 is member of the Ly6/aBgtx families. (A) Phylogenetic tree of the Ly6/aBgtx families showing the relationship between secreted snake toxins
and the GPI-anchored Ly6/uPAR family. SLURP-1 is phylogenetically more closely related to snake toxins than it is to the mammalian GPI-anchored receptors.
Phylogenetic tree calculation is based on a sequence distance method and utilizes the neighbor joining algorithm (41). (B) Comparison of the SLURP-1 model (left)
and the CD59 extracellular domain experimental NMR structure (right, PDB code: 1ERG). SLURP-1 cysteines are colored in yellow, as disulfide bridges of the
CD59 extracellular domain. Note the homologous disposition of CD59 disulfide bridges and SLURP-1 cysteines. Both proteins structurally adopt, or are predicted
to adopt, the characteristic ‘three-finger’ appearance of snake proteins. N- and C-terminal ends of the molecules are labeled.
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cells, which were cultured for 3 days before the medium was
harvested. After dialysis against buffer A (50mM sodium
phosphate; 300mM NaCl; pH 7.4), supernatants were incu-
bated with Talon resin (Clontech) and the native buffer protocol
provided. After washing, the fusion protein was eluted with
buffer A containing 150mM imidazole. The fractions contain-
ing SLURP-1 were either dialysed against buffer A or loaded
on a BioRad BioPrepSE-100/17gel filtration chromatography
column and eluted with buffer A to obtain pure recombinant
SLURP-1.
Treatment with N-glycosidase F
Approximately 10 mg of myc-His6-tagged SLURP-1 partially
purified either from insect or mammalian cells culture medium
was diluted in a solution of 25mM sodium phosphate (pH 7.0),
25mM EDTA, and 0.15% SDS and then heated at 100C for
5min. After the solution cooled, 10% Nonidet P-40 and 0.6U
N-glycosidase F (Roche) were added (final detergent concen-
trations, 0.1% SDS and 0.5% Nonidet P-40) and the mixture
was incubated at 37C for 20 h. The reaction was stopped by
adding SDS–PAGE sample buffer, followed by incubation at
100C for 5min. Samples were then loaded in 15% SDS–
PAGE and revealed with silver staining or western blotting,
using co-purified proteins as internal positive control for
N-glycosidase F activity.
Structural modeling
Three dimensional model of SLURP-1 was built by the
computer program 3D-PSSM (39) (www.sbg.bio.ic.ac.uk/
srvers/3dpssm). 3D-PSSM (three-dimensional position-specific
scoring matrix) uses structural alignments of homologous
proteins of similar three-dimensional structure in the structural
Figure 4. SLURP-1 can modulate nicotinic acetylcholine function in vitro. (A) Current responses before and after 5min exposure to 20 nM SLURP-1. Currents
were activated by a 2s application of 100mM ACh. (B) Effects of SLURP-1 are concentration-dependant, currents were activated by 200 or 300mM ACh. (C)
200 pM SLURP-1 shifted the ACh dose response curve (closed squares) to the left and increased Emax (solid circles). EC50 was 178mM for control and 68mM
after 2.5min exposure to SLURP-1 (200 pM). n¼ 6 for each data point.
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classification of proteins (SCOP) database to obtain a structural
equivalence of residues. These equivalences are used to extend
multiply aligned sequences obtained by standard sequence
searches. The resulting large superfamily-based multiple
alignment is converted into a PSSM. Combined with secondary
structure matching and solvation potentials, 3D-PSSM can
recognize structural and functional relationships between
homologous proteins (39).
Oocyte preparation and injection
X. laevis oocytes were isolated and prepared as described
previously (40). Oocytes were intranuclearly injected with 2 ng
of human a7 cDNA and kept in separate wells of a 96-well
microtitre plate at 18C. OR2 control medium consisted of
88mM NaCl, 2.5mM KCl, 10mM HEPES, 1mM MgCl2, and
2mM CaCl2, pH 7.4, adjusted with NaOH.
Electrophysiology
Experiments were carried out 2–4 days after cDNA injection.
Electrophysiological recordings were performed using a two-
electrode voltage-clamp (GeneClamp amplifier; Axon
Instruments, Union City, CA, USA); holding potential was
100mV. Electrodes were pulled from borosilicate glass and
contained 3M KCl. Solution exchanges were performed by an
automated system based around a liquid handling robot.
Oocytes were continuously superfused with OR2 except during
peptide incubation. Oocytes were maintained at 18C during
experiments. Dose–response curves were fit by the equation
y¼ Imax* {1/(1 þ (EC50/[ACh])n)}, where Imax is the maximal
normalized current amplitude, EC50 the half effective agonist
concentration, n the Hill coefficient and [ACh] the ACh
concentration.
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